The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they conta

Global Webcast Presentation (ASX: IMM,

NASDAQ: IMMP) Update on new TACTI-002 Phase II and initial INSIGHT-003 Phase 1 data presented at SITC 2022 A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease Date & Time Thursday, 10 November 2022, at 5 pm U.S. ET Friday,

November 11, at 9 am Australian Eastern Daylight Time (AEDT) Registration Webcast Link Exhibit 99.1

The purpose of the presentation is to

provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website

and/or the Company's filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or

warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions,

plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from

assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs

about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be

construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This presentation is authorised for release by the CEO of Immutep Limited. Forward-Looking Statements

Eftilagimod Alpha (efti): A

First-in-Class Soluble LAG-3 Protein

Cytotoxic T lymphocyte Antigen-4

(CTLA-4) Yervoy (anti-CTLA-4) approved 2011; commercial sales >$2 billion in 2021 Programmed Cell Death Protein-1 (PD-1) Keytruda & Opdivo (anti-PD-1) approved 2014; combined commercial sales >$24 billion in 2021 Lymphocyte Activating

Gene-3 (LAG-3)* Relatlimab (anti-LAG-3) approved 2022 in combination with Opdivo; BMS est. >$4 billion in NRA sales** in 2029 Immune system's role in controlling cancer has led to regulatory approval of immunotherapies targeting CTLA-4,

PD-1, and now LAG-3 checkpoints *Discovered by Immutep's CMO & CSO, Prof Fr d ric Triebel in 1990; **JPM 2022 Presentation; Non-Risk Adjusted Sales subject to positive registrational trials and health authority approval LAG-3:

Approved Checkpoint with Unique Characteristics LAG-3 is unique in that its inhibition on T cells & activation of dendritic cells engages the adaptive & innate immune systems against cancer offering significant potential to: (1) improve

responses to standard-of-care immunotherapy & chemotherapy, (2) limit emergence of resistance, (3) offer chemotherapy-free options in select indications.

Program Preclinical Phase I Phase II

Late Stage* Commercial Rights Solid Tumors (IO-IO-chemo) - INSIGHT-003 Metastatic Breast Cancer (Chemo-IO) - AIPAC 1st Line Head and Neck Squamous Cell Carcinoma (IO-IO) - TACTI-003a 2nd Line Head and Neck Squamous Cell Carcinoma (IO-IO) -

TACTI-002a 1st Line Non-Small Cell Lung Carcinoma (IO-IO) - TACTI-002a Solid Tumors (IO-IO) - INSIGHT-004 , b Undisclosed Global Rights Global Rights China Rights Undisclosed Global Rights Global Rights Global Rights Solid Tumors + Blood

Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Melanoma (IO-IO-Small Molecule Combo) Solid Tumors (IO-IO Combo) TNBC (Chemo-IO-Small Molecule Combo) Ulcerative Colitis Psoriasis Healthy Japanese and Caucasian Subjects

Eftilagimod Alpha (efti or IMP321) APC activating soluble LAG-3 protein LAG525 Antagonist Antibody Small Molecule Anti-LAG-3 ONCOLOGY AUTOIMMUNE DISEASE GSK'781 Depleting Antibody IMP761 Agonist Antibody Immutep LAG-3 Pipeline Information in

pipeline chart current as of September 2022;For EOC's China rights, Immutep may receive undisclosed milestones plus royalties; LAG525 - ClinicalTrials.gov (for Novartis' global rights, Immutep may receive undisclosed milestones plus

royalties); GSK2831781 - ClinicalTrials.gov (for GSK's global rights, Immutep may receive up to 64m in total upfront payments and milestones, plus royalties); * Late stage refers to Phase IIb clinical trials or more clinically advanced

clinical trials; # Conducted by EOC in China. Immutep has no control over either the trials. Investigator Initiated Trials, controlled by lead investigator and therefore Immutep has no control over this clinical trial; a In combination with

KEYTRUDA ; b In combination with BAVENCIO 2nd Line PD-X Refractory Non-Small Cell Lung Carcinoma (IO-IO) - TACTI-002a Soft Tissue Sarcoma (IO-IO-RT) Metastatic Breast Cancer & Other Solid Tumors (Chemo-IO & IO-IO)# Melanoma

(IO-IO) - TACTI-mel a

Efti: First-in-Class Positioning in

LAG-3 Oncology Landscape Immutep's proprietary soluble LAG-3Ig clinical candidate is a first-in-class antigen-presenting cell (APC) agonist via MHC II that capitalizes on LAG-3's unique characteristics LAG-3 Human IgG1 Eftilagimod alpha

(Efti) Efti, a soluble LAG-3 protein, acts as a key to unlock broad activation of the immune system Capitalizes on LAG-3's unique ability to drive adaptive & innate immune systems against cancer Has high affinity for a subset of MHC II

ligand on APCs Its activation of APCs drives broad stimulation of multiple anti-tumor cells, as well as a significant increase in IFN- and CXCL10 serum biomarkers for systemic TH1 response Compelling pairing capabilities Excellent safety

profile drives high suitability for combination approaches Synergistic activity & encouraging clinical results with multiple agents including anti-PD-1, anti-PD-L1, and chemotherapy Enhances clinical activity of anti-PD-1 across PD-L1 status,

including low & negative PD-L1 tumors MHC II APC Dendritic Cells T-cells Monocytes NK Cells APC activation with Efti Anti-tumor immune cell activation Efti Pushing the Accelerator on the Immune System

TACTI-002 Phase II Trial - Part

A: Efti + Pembrolizumab Combination in 1st Line Non-Small Cell Lung Cancer (1L NSCLC)

Treatment Options in 1L NSCLC Limited

by Durability & Tolerability Well-tolerated treatment options that synergize with SOC and improve outcomes across PD-L1 status, including negative & low PD-L1 tumors, are necessary in frontline NSCLC. Efti in combination with anti-PD-1

immunotherapy has significant potential to fill this unmet need. 1L NSCLC Epidemiology1,2 - 1.87 million NSCLC diagnoses per annum - - Most frequent cause of cancer death (18%) - - 1.3 million patients develop

metastatic disease & are eligible to receive anti-PD-(L)1 - 1 Calculated from Global Cancer Observatory (WHO), 2020 data; 2 Informa Pharma Intelligence Report 2018 for US, Japan and EU5 Unmet need in 1L NSCLC as median Overall Survival

still <24 months for most patients High discontinuation rates due to toxicity limits Duration of Response of checkpoint & chemo combinations Patients with low PD-L1 status have poorer responses to checkpoint therapy (TPS <50% = ~70%

Phase II Trial Evaluating Efti + Pembro

in 1L NSCLC TACTI-002: Two ACTive Immunotherapeutics in NSCLC & HNSCC Baseline characteristics for PD-L1 All Comer Trial Part A (N=114) Age, median (range), years 67 (44-85) Sex, n (%) Female / Male 30 (26.3) / 84 (73.7) ECOG PS score, n (%) 0 /

1 43 (37.7) / 71 (62.3) Smoking status, n (%) Current or Ex-smoker / Non-smoker 108 (94.7) / 6 (5.3) Histology, n (%) Squamous / Non-squamous / Unknown 40 (35.1) / 72 (63.2) / 2 (1.8) Metastatic disease, n (%) Yes / No 113 (99.1) / 1 (0.9) PD-L1

expression TPS1, n (%) < 1% 1-49% 50% 37 (34.3) 42 (38.9) 29 (26.9) Previous therapy, n (%) Radiotherapy Surgery Systemic therapy for non-metastatic disease 38 (33.3) 23 (20.2) 26 (22.8) Data cut-off July 1, 2022 1 Central assessment of

PD-L1 TPS using Dako PD-L1 IHC 22C3 pharmDx for 90 pts. For 18 pts, local assessment was used due to non evaluable central assessment results. TPS: tumor proportion score. TACTI-002/KEYNOTE-798: 1st Line Non-Small Cell Lung Cancer (Part A) All-comer

trial for 1L NSCLC patients with all levels of PD-L1 expression ~75% of patients have PD-L1 TPS of <50% 34.3% of patients have PD-L1 TPS of <1% 99.1% had metastatic disease at study entry

Encouraging Clinical Results;

Primary Objective Achieved TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Response iRECIST4 n (%) RECIST 1.14 n (%) Complete Response 1 (0.9) 1 (0.9) Partial Response 45 (39.5) 43 (37.8) Stable Disease 37 (32.5) 37

(32.5) Progression 18 (15.8) 20 (17.5) Not Evaluable1 13 (11.4) 13 (11.4) ORR, (ITT=114); [95% CI]2 46 (40.4) ; [31.3-50.0] 44 (38.6) ; [29.6-48.2] ORR (EVAL3 =101); [95% CI]2 46 (45.5) ;

[35.6-55.8] 44 (43.6) ; [33.7-53.8] ORR & DCR by iRECIST, n (%) <1%, N=32 1-49%, N=38 50%, N=20 1% N=58 ORR [95% CI]2 10 (31.3) [16.1-50.0] 17 (44.7) [ 28.6-61.7] 11

(55.0) [31.5-76.9] 28 (48.3) [35.0-61.8] DCR [95% CI]2 21 (65.6) [ 46.8-81.4] 30 (78.9) [62.7-90.5] 16 (80.0) [56.3-94.3] 46 (79.3) [66.7-88.8] Note:

ORR for combined central + local PD-L1 (N=108): ORR for PD-L1 TPS <1% of 27%; ORR for 1-49% of 42.9%; ORR for 50% of 51.7%; ORR for 1% of 46.5%. Tumor Response by PD-L1 status5 ORR - PD-L1 all comer Data cut-off July 1, 2022;

ITT: Intention-to-treat (N=114). EVAL: Evaluable population (N=101). 1. Pts with no on-study post-baseline tumor staging for any reason. 2. 95% confidence intervals calculated using Clopper-Pearson method. 3. All pts with 1 on-study

post-baseline tumor staging. 4. Unconfirmed. 5. Central assessment of PD-L1 TPS using Dako IHC 22C3 pharmDx for 90 pts. 6. Confirmed ORR by iRECIST: 35.1% (95% CI: 26.4-44.6) Primary Objective achieved (ORR > 35%) Responses confirmed in 87% of

cases6 Responses comparable between iRECIST and RECIST 1.1. Comparable ORR for squamous and non-squamous histologies 45% ORR for TPS of 1-49% and >30% & for PD-L1 negative patients Tumor Response, n (%) Squamous, N=40

Non-squamous, N=72 ORR [95% CI]2 15 (37.5) [22.7-54.2] 29 (40.3) [28.9-52.5] DCR [95% CI]2 33 (82.5) [67.2-92.7] 48 (66.7) [54.6-77.3] Note: 2 pts with tumor type not otherwise specified had a PR as BOR. Tumor

Response by tumor type

Responses Across Entire PD-L1

Spectrum Data cut-off July 1, 2022; 1 all patients with 1 post-baseline CT scan; N=103; 2 PD-L1 assessed by central assessment (Dako kit), n=82; 3 local assessment included due to non evaluable central assessment results, n=16; 4 no results

available for neither central nor local testing, n=5. TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) 4 2, 3 Responses are deep and across all PD-L1 subgroups ~70 % of patients have a decrease of target lesions

Time (months) Remaining in Response

(%) Deep & Durable Responses: Interim Median DoR 21.6 Months TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Efficacy: Change in Tumor Size Over Time Interim Median Duration of Response (DoR) DoR by iRECIST (N=40) Events, n (%) 10 (25.0) Median, months

[95% CI]4 21.6 [17.3-30.0] Treatment concluded Time (months) % change from baseline Response onset is early & responses are long-lasting: interim mDoR 21.6 months Less than 10% of responding patients progress within 6 months Data cut-off July 1,

2022 1 all pts with 1 post-baseline CT scan with evaluable response; N=101. Pts are listed with iPR / iCR response regardless if confirmed or unconfirmed. 2 by iRECIST. 3 all patients with confirmed response by iRECIST. 4 95% confidence

intervals calculated using Clopper-Pearson method Best overall response: iUPD/iCPD iCR iPR iSD ongoing pts remaining on study at data cut-off (N=24) 2, 3 1

Promising Progression Free Survival

(PFS) TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) PD-L1 TPS (central) Median, months [95% CI] Events, n (%) 50% (N=20) 1-49% (N=38) <1% (N=32) 1% (N=58) 16.7 [4.0-16.8] 8.3 [4.4-15.7] 4.2 [3.6-6.1] 9.3 [6.1-15.7] 10 (50.0) 23

(60.5) 26 (81.3) 34 (58.6) PFS1 by PD-L1 status PFS1 - PD-L1 all comer (ITT) PFS1 (N=114) Events, n (%) 73 (64.0) Median, months [95% CI] 6.6 [4.6-9.3] 6-month PFS rate, % 56.2 Progression-Free Survival (%) Progression-Free Survival (%) Time

(Months) Time (Months) Data cut-off July 1, 2022 1 by iRECIST. 2 95% confidence intervals calculated using Clopper-Pearson method. *mPFS of central & local assessment was 9.8 months for PD-L1 TPS >1%, 8.3 months for PD-L1 TPS 1-49%, 11.8

months for PD-L1 >50%, and 4.2 months for PD-L1 <1% Note: figures have been cropped for visualization purposes

Initial Efti + Pembrolizumab

Pharmacodynamic Data TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Key takeaways: Significant increase in IFN- and CXCL10 serum biomarkers for systemic TH1 response at 3 and 6 months compared to baseline. Substantiates efti's unique

stimulation of the immune system, also seen in randomized AIPAC Phase IIb trial in Breast Cancer. Increased IFN- levels have been associated with objective tumor responses with anti-PD-1 therapy1 & CXCL10 has been shown to contribute to

"hot" tumor microenvironment2 Increase is seen early (<24 hours) after first efti administration3 Blood samples collected pre-efti dosing at baseline, after 3 months (n=68) and 6 months (n=36), 2 weeks after the previous efti dosing

-> minimal residual effect Data cut-off: July 1, 2022; Note: Plasma levels of IFN-g and CXCL10/IP10 are shown as mean of % change to baseline. Two-sided Wilcoxon matched-pair signed rank test on timepoint versus baseline are shown 1 Cancer Sci.

2017 May; 108(5): 1022-1031. 2 SCIENCE IMMUNOLOGY 22 Jul 2022, Vol 7, Issue 73 DOI: 10.1126/sciimmunol.abq6509. 3 Data not shown. * p-value <0.05 ** p-value <0.01 Efti dosing Blood sampling

TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Safety parameter1 n (%) Adverse reactions with fatal outcome 2 3 (2.6) Serious adverse reactions2 12 (10.5) Grade 3 adverse reactions2 14 (12.3) Adverse

reactions leading to discontinuation of treatment2 11 (9.6) Frequent TEARs (incidence 10%) by PT related to treatment2 Adverse event by PT, n (%) Any grade G3 G4 G5 Pruritus 23 (20.2) N/A N/A N/A Asthenia 22 (19.3) N/A N/A

N/A Rash 15 (13.2) N/A N/A N/A Diarrhoea 12 (10.5) 1 (0.9) N/A N/A Fatigue 12 (10.5) 1 (0.9) N/A N/A Overview of adverse reactions Median efti exposure was 24.7 weeks (range 1- 58.0) and 24.2 weeks for pembro (range 0.1-103.3). 6 pts completed 2

years of treatment and 24 pts still on therapy at data cut-off. 26.3% of pts had any type of local injection site reactions3 G1+2. No reactions G3 were reported. irAEs2 >2% were: hypothyroidism (6.1%), pneumonitis (4.4%), hyperthyroidism

(3.5 %), and myositis (2.6%). Rate of discontinuation due to drug related adverse events comparable to pembrolizumab monotherapy** Safety profile, including immune mediated adverse events, comparable to pembrolizumab monotherapy except for the

addition of any type of local injection site reactions** Preliminary data, cut-off July 1, 2022; (**) - Source: KN042; KN001; KN024, TACTI-002); 1 rated according to the current NCI CTCAE (v5.0); 2 relationship to efti and/or pembrolizumab could not

be ruled out; 3 any PT containing injection site PT ~ Preferred Term; TEAE - treatment emergent adverse event

TACTI-002/KEYNOTE-798: 1L NSCLC

(Part A) * Efti + Pembro ORR by iRECIST, unconfirmed, Total (N=114) and PD-L1 TPS subgroups (N=90). Data cut-off July 1, 2022. Pembrolizumab ( pembro') mono efficacy used for benchmarking for ORR: Total calculation based on KN-001;

KN-042 and on adjustment for the same PD-L1 subgroup distribution as in TACTI-002. < 1 % TPS: calculation based on limited data set from KN-001 (1st & 2nd line altogether). 1-49%, 50%, and 1 % TPS based on KN-001, KN-042. #

PFS by PD-L1 status (N=90) using central assessment for 90 patients. Pembro mono efficacy used for benchmarking: 1-49%, 50%, and 1 % TPS based on KN-001, KN-042. Lancet https://doi.org/10.1016/S0140-6736(18)32409-7, Oral Presentation

2018 ASCO, EPAR assessment report, N Engl J Med 2016; 375:1823-33; KN-024 update J Clin Oncol 2019, KN-024 J Clin Oncol 2021 Benchmarking against Pembrolizumab Monotherapy: Strong ORR & PFS Across PD-L1 Spectrum 8.3 months 4.2 months 9.3 months

5.4 months 16.7 months 7.1 months (by PD-L1 TPS Score) Efti + pembro Pembro mono TPS 1-49% TPS >1% TPS >50% Median Progression Free Survival# (PFS) Time (months) Overall Response Rate (ORR) (with 95% confidence interval) TPS 1-49% TPS >1%

TPS >50% TPS <1% Overall Efti + pembro Pembro mono Key Takeaways Superior ORR/PFS across all PD-L1 levels ORR at >1% and 1-49% confidence intervals do not overlap with ORR reported for pembro monotherapy Sustained, durable responses similar

to pembro monotherapy Well tolerated & safety profile remains similar to pembro alone Efti has potential to substantially increase # of patients that respond to anti-PD-1 therapy, due to its orthogonal mechanism of action Of note, efti +

pembrolizumab has Fast Track Designation in >1% TPS in 1st Line NSCLC Confidence intervals do not overlap

ORR, mPFS and DoR data for

pembrolizumab was derived from respective publications of KN-001; KN-042; KN-407; KN-189 Benchmarking against Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination Key Takeaways ORR & mPFS well ahead of pembro mono and similar

range to chemo-IO DoR well ahead chemo-IO and ahead of pembro mono, despite TACTI-002 having 34.3% patients with TPS <1% vs pembro mono results from TPS >1% group On an individual basis, these key parameters for efti+pembro combination are

impressive. Taken together, efti+pembro holds significant promise to positively impact patient outcomes. TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) (TPS >0%) Pembro mono (TPS >1%)

INSIGHT-003 Phase 1 Trial: Efti +